Clinical Trial Update: Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

A Phase 2 cross-over trial of a subcutaneous study drug for patients with mild to moderate asthma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Subcutaneous Study Drug

Snippet

Sponsor: Palatin Technologies, Inc | Conditions: Asthma | Phase 2 | Status: WITHDRAWN